ATE439861T1 - Verfahren zur modulierung von cd200-rezeptoren - Google Patents
Verfahren zur modulierung von cd200-rezeptorenInfo
- Publication number
- ATE439861T1 ATE439861T1 AT03716515T AT03716515T ATE439861T1 AT E439861 T1 ATE439861 T1 AT E439861T1 AT 03716515 T AT03716515 T AT 03716515T AT 03716515 T AT03716515 T AT 03716515T AT E439861 T1 ATE439861 T1 AT E439861T1
- Authority
- AT
- Austria
- Prior art keywords
- modulating
- receptors
- methods
- agonists
- antagonists
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/12—Antidiarrhoeals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/02—Nasal agents, e.g. decongestants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P39/00—General protective or antinoxious agents
- A61P39/02—Antidotes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/75—Agonist effect on antigen
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/77—Internalization into the cell
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Pulmonology (AREA)
- Cardiology (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Heart & Thoracic Surgery (AREA)
- Dermatology (AREA)
- Hospice & Palliative Care (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Physical Education & Sports Medicine (AREA)
- Transplantation (AREA)
- Otolaryngology (AREA)
- Gastroenterology & Hepatology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Vascular Medicine (AREA)
- Psychology (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US36451302P | 2002-03-15 | 2002-03-15 | |
PCT/US2003/007647 WO2003077947A1 (en) | 2002-03-15 | 2003-03-13 | Methods of modulating cd200 receptors |
Publications (1)
Publication Number | Publication Date |
---|---|
ATE439861T1 true ATE439861T1 (de) | 2009-09-15 |
Family
ID=28041929
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
AT03716515T ATE439861T1 (de) | 2002-03-15 | 2003-03-13 | Verfahren zur modulierung von cd200-rezeptoren |
Country Status (16)
Country | Link |
---|---|
US (3) | US20030223991A1 (de) |
EP (3) | EP1482973B1 (de) |
JP (4) | JP2005529587A (de) |
AT (1) | ATE439861T1 (de) |
AU (3) | AU2003220219A1 (de) |
CA (1) | CA2478803A1 (de) |
CY (1) | CY1109521T1 (de) |
DE (1) | DE60328870D1 (de) |
DK (1) | DK1482973T3 (de) |
ES (1) | ES2330211T3 (de) |
MX (1) | MXPA04008937A (de) |
NZ (2) | NZ553470A (de) |
PT (1) | PT1482973E (de) |
SI (1) | SI1482973T1 (de) |
WO (1) | WO2003077947A1 (de) |
ZA (2) | ZA200407384B (de) |
Families Citing this family (29)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2000070045A1 (en) * | 1999-05-13 | 2000-11-23 | Medical Research Council | Ox2 receptor homologs |
ATE423571T1 (de) | 2001-10-12 | 2009-03-15 | Schering Corp | Verwendung von bispezifischen antikörpern gegen einen aktivierenden rezeptor fcepsilonri und gegen einen inhibierenden rezeptor ox2ra (cd200ra) zur regulierung der immunantworten |
EP1482973B1 (de) * | 2002-03-15 | 2009-08-19 | Schering Corporation | Verfahren zur modulierung von cd200-rezeptoren |
US20050287603A1 (en) * | 2002-06-07 | 2005-12-29 | Gorczynski Reginald M | Modulation of bone development |
JP2006512396A (ja) * | 2002-12-27 | 2006-04-13 | シェーリング コーポレイション | 免疫寛容を誘導および維持する方法 |
JP2007518827A (ja) * | 2004-02-02 | 2007-07-12 | シェーリング コーポレイション | Cd200およびcd200rを調節する方法 |
JP4919453B2 (ja) * | 2005-04-07 | 2012-04-18 | 独立行政法人理化学研究所 | 炎症性疾患の予防又は治療剤 |
WO2007149312A2 (en) | 2006-06-16 | 2007-12-27 | The Trustees Of The University Of Pennsylvania | Methods and compositions for inhibiting or reducing hair loss, acne, rosacea, prostate cancer, and bph |
CN101679519A (zh) * | 2006-12-22 | 2010-03-24 | 先灵公司 | Cd200r的抗体 |
US20100104582A1 (en) * | 2007-01-11 | 2010-04-29 | Boehringer Ingelheim International Gmbh | CD200 and its receptor, CD200R, modulate bone mass via the differentiation of osteoclasts |
WO2009004339A2 (en) * | 2007-07-03 | 2009-01-08 | Imperial Innovations Limited | Compositions and methods relating to manipulation of the myeloid immune compartment during respiratory infection |
EP2432805A1 (de) * | 2009-05-20 | 2012-03-28 | Schering Corporation | Modulation von pilr-rezeptoren zur behandlung von sepsis |
EP2432499A2 (de) | 2009-05-20 | 2012-03-28 | Schering Corporation | Modulation von pilr-rezeptoren zur behandlung mikrobieller infektionen |
WO2011084357A1 (en) | 2009-12-17 | 2011-07-14 | Schering Corporation | Modulation of pilr to treat immune disorders |
EP3153521B1 (de) | 2010-03-26 | 2019-09-04 | Trustees of Dartmouth College | Vista-regulatorisches t-zellen-mediator-protein, vista-bindende wirkstoffe und verwendung davon |
US10745467B2 (en) | 2010-03-26 | 2020-08-18 | The Trustees Of Dartmouth College | VISTA-Ig for treatment of autoimmune, allergic and inflammatory disorders |
US20150231215A1 (en) | 2012-06-22 | 2015-08-20 | Randolph J. Noelle | VISTA Antagonist and Methods of Use |
US9890215B2 (en) | 2012-06-22 | 2018-02-13 | King's College London | Vista modulators for diagnosis and treatment of cancer |
AU2013277051B2 (en) * | 2012-06-22 | 2018-06-07 | King's College London | Novel VISTA-Ig constructs and the use of VISTA-Ig for treatment of autoimmune, allergic and inflammatory disorders |
EP3552628A1 (de) | 2012-09-07 | 2019-10-16 | The Trustees Of Dartmouth College | Vista-modulatoren zur diagnose und behandlung von krebs |
JP5854432B2 (ja) * | 2012-09-28 | 2016-02-09 | 森永乳業株式会社 | アレルギー反応検出法 |
EP3712174B1 (de) | 2013-12-24 | 2022-03-16 | Janssen Pharmaceutica NV | Anti-vista-antikörper und -fragmente |
US11014987B2 (en) | 2013-12-24 | 2021-05-25 | Janssen Pharmaceutics Nv | Anti-vista antibodies and fragments, uses thereof, and methods of identifying same |
US11123426B2 (en) | 2014-06-11 | 2021-09-21 | The Trustees Of Dartmouth College | Use of vista agonists and antagonists to suppress or enhance humoral immunity |
CN107405398A (zh) | 2014-12-05 | 2017-11-28 | 伊穆奈克斯特股份有限公司 | 鉴定vsig8作为推定vista受体及其用以产生vista/vsig8激动剂和拮抗剂的用途 |
CN114805576A (zh) | 2015-06-24 | 2022-07-29 | 詹森药业有限公司 | 抗vista抗体和片段 |
WO2017137830A1 (en) | 2016-02-12 | 2017-08-17 | Janssen Pharmaceutica Nv | Anti-vista (b7h5) antibodies |
AU2017250294B2 (en) | 2016-04-15 | 2022-07-21 | Immunext Inc. | Anti-human VISTA antibodies and use thereof |
TWI749367B (zh) * | 2018-09-14 | 2021-12-11 | 美商美國禮來大藥廠 | Cd200r促效劑抗體及其用途 |
Family Cites Families (33)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4946778A (en) | 1987-09-21 | 1990-08-07 | Genex Corporation | Single polypeptide chain binding molecules |
US5202267A (en) | 1988-04-04 | 1993-04-13 | Hygeia Sciences, Inc. | Sol capture immunoassay kit and procedure |
US5468468A (en) | 1989-02-09 | 1995-11-21 | The United States Of America, As Represented By The Secretary Of The Department Of Health & Human Services | Method for making a monoclonal antibody, monoclonal antibodies to α PD |
US6176962B1 (en) | 1990-02-28 | 2001-01-23 | Aclara Biosciences, Inc. | Methods for fabricating enclosed microchannel structures |
DE69113162T2 (de) * | 1990-08-02 | 1996-03-14 | Hoffmann La Roche | Antiallergische Mischung. |
US5856457A (en) | 1991-03-29 | 1999-01-05 | Genentech, Inc. | Nucleic acids encoding a human IL-8 receptor |
US5440021A (en) | 1991-03-29 | 1995-08-08 | Chuntharapai; Anan | Antibodies to human IL-8 type B receptor |
US5932448A (en) | 1991-11-29 | 1999-08-03 | Protein Design Labs., Inc. | Bispecific antibody heterodimers |
US6129914A (en) | 1992-03-27 | 2000-10-10 | Protein Design Labs, Inc. | Bispecific antibody effective to treat B-cell lymphoma and cell line |
US5532210A (en) | 1994-06-08 | 1996-07-02 | E. I. Du Pont De Nemours And Company | High temperature superconductor dielectric slow wave structures for accelerators and traveling wave tubes |
US6132764A (en) | 1994-08-05 | 2000-10-17 | Targesome, Inc. | Targeted polymerized liposome diagnostic and treatment agents |
US5919816A (en) | 1994-11-14 | 1999-07-06 | Bionumerik Pharmaceuticals, Inc. | Formulations and methods of reducing toxicity of antineoplastic agents |
WO1997003715A1 (en) | 1995-07-21 | 1997-02-06 | The General Hospital Corporation | Method and apparatus of enhancing the delivery of a pharmaceutical formulation |
US6096728A (en) | 1996-02-09 | 2000-08-01 | Amgen Inc. | Composition and method for treating inflammatory diseases |
JP3888695B2 (ja) | 1996-05-27 | 2007-03-07 | 株式会社医学生物学研究所 | ヒトlect2に対する抗体、それを産生する細胞、その測定法及び測定用キット |
US6056973A (en) | 1996-10-11 | 2000-05-02 | Sequus Pharmaceuticals, Inc. | Therapeutic liposome composition and method of preparation |
JPH10212242A (ja) * | 1996-11-27 | 1998-08-11 | Tosoh Corp | 新規血小板増多剤 |
US6294170B1 (en) | 1997-08-08 | 2001-09-25 | Amgen Inc. | Composition and method for treating inflammatory diseases |
US5948627A (en) | 1997-05-30 | 1999-09-07 | One Lambda | Immunobead flow cytometric detection of anti-HLA panel-reactive antibody |
US6342220B1 (en) | 1997-08-25 | 2002-01-29 | Genentech, Inc. | Agonist antibodies |
US6989435B2 (en) * | 1997-09-11 | 2006-01-24 | Cambridge University Technical Services Ltd. | Compounds and methods to inhibit or augment an inflammatory response |
US5842787A (en) | 1997-10-09 | 1998-12-01 | Caliper Technologies Corporation | Microfluidic systems incorporating varied channel dimensions |
JPH11246435A (ja) * | 1997-10-29 | 1999-09-14 | Ajinomoto Co Inc | 免疫調整剤 |
US6312689B1 (en) | 1998-07-23 | 2001-11-06 | Millennium Pharmaceuticals, Inc. | Anti-CCR2 antibodies and methods of use therefor |
EP1100869A4 (de) * | 1998-07-30 | 2005-04-27 | Human Genome Sciences Inc | 98 menschliche sekretierte proteine |
WO2000032634A1 (en) | 1998-12-01 | 2000-06-08 | Protein Design Labs, Inc. | Humanized antibodies to gamma-interferon |
WO2000070045A1 (en) * | 1999-05-13 | 2000-11-23 | Medical Research Council | Ox2 receptor homologs |
CA2417874C (en) * | 2000-08-03 | 2012-10-02 | Transplantation Technologies Inc. | Use of ox-2 inhibitors for the treatment of cancer |
WO2002088164A1 (en) | 2001-04-26 | 2002-11-07 | Immunex Corporation | Human ox2 receptors |
US7368535B2 (en) * | 2001-05-24 | 2008-05-06 | Trillium Therapeutics Inc. | CD200 receptors |
ATE423571T1 (de) * | 2001-10-12 | 2009-03-15 | Schering Corp | Verwendung von bispezifischen antikörpern gegen einen aktivierenden rezeptor fcepsilonri und gegen einen inhibierenden rezeptor ox2ra (cd200ra) zur regulierung der immunantworten |
US20040126777A1 (en) * | 2002-01-28 | 2004-07-01 | Bhatt Ramesh Rajani | Lp mammalian proteins; related reagents |
EP1482973B1 (de) * | 2002-03-15 | 2009-08-19 | Schering Corporation | Verfahren zur modulierung von cd200-rezeptoren |
-
2003
- 2003-03-13 EP EP03716515A patent/EP1482973B1/de not_active Expired - Lifetime
- 2003-03-13 WO PCT/US2003/007647 patent/WO2003077947A1/en active Application Filing
- 2003-03-13 PT PT03716515T patent/PT1482973E/pt unknown
- 2003-03-13 DK DK03716515T patent/DK1482973T3/da active
- 2003-03-13 AU AU2003220219A patent/AU2003220219A1/en not_active Abandoned
- 2003-03-13 ES ES03716515T patent/ES2330211T3/es not_active Expired - Lifetime
- 2003-03-13 DE DE60328870T patent/DE60328870D1/de not_active Expired - Lifetime
- 2003-03-13 EP EP09163830A patent/EP2100617A1/de not_active Withdrawn
- 2003-03-13 MX MXPA04008937A patent/MXPA04008937A/es active IP Right Grant
- 2003-03-13 NZ NZ553470A patent/NZ553470A/en not_active IP Right Cessation
- 2003-03-13 CA CA002478803A patent/CA2478803A1/en not_active Abandoned
- 2003-03-13 SI SI200331692T patent/SI1482973T1/sl unknown
- 2003-03-13 US US10/389,231 patent/US20030223991A1/en not_active Abandoned
- 2003-03-13 NZ NZ570998A patent/NZ570998A/en not_active IP Right Cessation
- 2003-03-13 JP JP2003576000A patent/JP2005529587A/ja active Pending
- 2003-03-13 EP EP10183878A patent/EP2322218A1/de not_active Withdrawn
- 2003-03-13 AT AT03716515T patent/ATE439861T1/de active
-
2004
- 2004-09-14 ZA ZA200407384A patent/ZA200407384B/xx unknown
-
2006
- 2006-03-03 JP JP2006058745A patent/JP2006206598A/ja active Pending
- 2006-06-29 US US11/478,778 patent/US20060240010A1/en not_active Abandoned
-
2007
- 2007-06-26 AU AU2007202938A patent/AU2007202938B2/en not_active Ceased
-
2008
- 2008-03-10 US US12/045,153 patent/US8263070B2/en not_active Expired - Fee Related
-
2009
- 2009-10-26 CY CY20091101112T patent/CY1109521T1/el unknown
-
2010
- 2010-03-04 ZA ZA2010/01595A patent/ZA201001595B/en unknown
-
2011
- 2011-04-20 AU AU2011201824A patent/AU2011201824A1/en not_active Abandoned
- 2011-06-16 JP JP2011134634A patent/JP2011178812A/ja not_active Withdrawn
- 2011-06-16 JP JP2011134635A patent/JP2011178813A/ja not_active Withdrawn
Also Published As
Publication number | Publication date |
---|---|
JP2006206598A (ja) | 2006-08-10 |
NZ553470A (en) | 2008-10-31 |
JP2011178813A (ja) | 2011-09-15 |
WO2003077947A1 (en) | 2003-09-25 |
MXPA04008937A (es) | 2005-06-17 |
DK1482973T3 (da) | 2009-12-07 |
PT1482973E (pt) | 2009-11-20 |
JP2005529587A (ja) | 2005-10-06 |
NZ570998A (en) | 2010-08-27 |
EP1482973A4 (de) | 2006-03-08 |
AU2007202938A1 (en) | 2007-07-19 |
EP1482973B1 (de) | 2009-08-19 |
US20060240010A1 (en) | 2006-10-26 |
JP2011178812A (ja) | 2011-09-15 |
ZA200407384B (en) | 2010-05-26 |
SI1482973T1 (sl) | 2010-01-29 |
AU2003220219A1 (en) | 2003-09-29 |
CA2478803A1 (en) | 2003-09-25 |
US8263070B2 (en) | 2012-09-11 |
EP1482973A1 (de) | 2004-12-08 |
DE60328870D1 (de) | 2009-10-01 |
ZA201001595B (en) | 2012-11-28 |
US20080166353A1 (en) | 2008-07-10 |
AU2007202938B2 (en) | 2011-01-20 |
US20030223991A1 (en) | 2003-12-04 |
ES2330211T3 (es) | 2009-12-07 |
EP2322218A1 (de) | 2011-05-18 |
EP2100617A1 (de) | 2009-09-16 |
CY1109521T1 (el) | 2014-08-13 |
AU2011201824A1 (en) | 2011-05-19 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
DE60328870D1 (de) | Verfahren zur modulierung von cd200-rezeptoren | |
DE60025368D1 (de) | Verfahren zum identifizieren von prostaglandin d2 rezeptor modulatoren | |
DE69033308T2 (de) | Decahydro-isochinolin-derivate | |
NO20064193L (no) | fremgangsmate for a modulere cytokinaktivitet, beslektede reagenser | |
IS5113A (is) | Notkun antagónista CB1-viðtaka til meðhöndlunar löngunartruflana | |
DE60027405D1 (de) | Verfahren zur steigerung der aktivität von haustieren | |
WO2005074985A3 (en) | Methods of modulating cd200 and cd200r | |
DE60326527D1 (de) | Verfahren und Gerät zur Ultraschallkontrastbildformung unter Benutzung von gestuften Chirp-Wellenformen | |
DE60335216D1 (de) | Adiponektin-rezeptor und dafür kodierendes gen | |
ATE354364T1 (de) | Verwendung von at-1 rezeptorantagonisten oder at- 2 rezeptormodulatoren zur behandlung von erkrankungen, die mit einer erhöhung an at-1 oder at-2 rezeptoren verbunden sind | |
DE60020571D1 (de) | Verfahren und vorrichtung zur unterscheidung und zählung von leukozyten | |
DE60209296D1 (de) | Verfahren und Apparat zur Reinigung der Halshaut von Schlachtgeflügel | |
DE60021960D1 (de) | Verfahren zur Kompensation von Neigung und/oder Defokussierung, und Vorrichtung für dasselbige | |
ES2055036T3 (es) | Antagonistas tetrazolicos de receptores de aminoacidos excitadores. | |
ATE432350T1 (de) | G-protein gekoppelte rezeptoren | |
DE69524623T2 (de) | Verwendung von cck-b rezeptor antagonisten zur behandlung von schlafstörungen | |
DE60033576D1 (de) | Methoden zum screening knochenmorphogenetishemimetika | |
MXPA05009743A (es) | Composiciones con actividad hematopoyetica e inmune. | |
DE60032077D1 (de) | Verfahren zur dehalogenierung von kohlenwasserstoffhaltigen kohlenstoff-kohlenstoff doppelbindungen | |
DE50001711D1 (de) | Vorrichtung und verfahren zur verklebung von fügeteilen | |
DE69801786D1 (de) | Verfahren, Vorrichtung und Produkt zur Verlängerung von menschlichem Haar | |
ATE545866T1 (de) | Liganden von g-protein-gekoppelten rezeptoren und verfahren | |
DE69803031D1 (de) | Verfahren zur Informationsübertragung über eine Infrarotverbindung und Einrichtung zum Durchführen des Verfahrens | |
DE29609743U1 (de) | Vorrichtung zum Erfassen von Arbeits- bzw. Anwesenheitszeiten von Personen | |
WO2003100439A3 (en) | Receptor and screening methods |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
UEP | Publication of translation of european patent specification |
Ref document number: 1482973 Country of ref document: EP |